U.K. Biotech Start-up, Oxford Immune Algorithmics (OIA) Successfully Completes QMS ISO 13485

Share this
Share on facebook
Share on twitter
Share on print
Share on email

Reading, June 1, 2022. Oxford Immune Algorithmics (OIA), the creators of Algocyte, is delighted to announce it has successfully received ISO 13485 certification status from NQA. It demonstrates the company’s commitment to best practices in producing quality medical devices for healthcare professionals and users. Oxford Immune Algorithmics’ are leaders in rapid at-home testing for AI-driven immune health monitoring.

Medical device regulatory agencies worldwide recognise the QMS ISO 13485 certification as the quality standard for medical device manufacturers. The certification attests to the high standard, conforms to medical device requirements in multiple areas, including design, testing, and manufacturing, and harmonises medical device regulations. It confirms the company’s medical device meets the high standards of healthcare professionals’ and consumers’ compliance safety standards. 

OIA’s AI-driven solution, Algocyte, monitors the immune system using responsible AI that reasons like a human medical expert. It can explain its decisions, empowering both patients and clinicians. 

Algocyte will radically change global healthcare from population-wide reference values to personalised immune system monitoring and a patient-centric approach.

Oxford Immune Algorithmics (OIA) is an award-winning AI company, incubated by the University of Oxford, that specialises in rapid at-home testing for immune health monitoring.  It uses the best of human and computational intelligence to deliver precise and individualised healthcare to everyone and rid the world of preventable diseases.

Sign up to receive more information